Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for Lamictal, Zione
March 27, 2017
- Orphan Designation Granted for Olaparib, 3 Other Drugs
March 27, 2017
- Cabinet OKs PMDA’s Review Fee Raise from April 1
March 27, 2017
- MHLW OKs Sovaldi for Genotypes 3-6, Opdivo for Head and Neck Cancer
March 27, 2017
- MHLW Poised to Review System Designs to Prevent Counterfeits: Minister
March 24, 2017
- No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
March 23, 2017
- Clinical Research Bill Passes Lower House
March 23, 2017
- MHLW Orders Label Revisions for 44 APIs in Sleep/Anxiolytic/Epilepsy Agents
March 21, 2017
- MHLW Unveils Revised Label Format; Notification Due Out Early FY2017
March 21, 2017
- MHLW Ordinance Will Close Loopholes in Clinical Research Bill’s Funding Disclosure Rules: Bureau Chief
March 21, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Japan Healthcare Spending Logs Slight Rise on Subdued Hep C Sales in April-September
March 17, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
- AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017
- Optimal Use Guidelines for Additional Indications to Be Reported to Chuikyo after Issuance
March 16, 2017
- Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
- Chuikyo Subcommittee OKs 5-Scale Rating for Cost Effective Assessments
March 16, 2017
- Spontaneous Reporting Required Even When Causal Relationship Is Unclear: MHLW
March 16, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…